Edition:
United States

Onconova Therapeutics Inc (ONTX.OQ)

ONTX.OQ on NASDAQ Stock Exchange Capital Market

1.36USD
3:59pm EST
Change (% chg)

$-0.04 (-2.86%)
Prev Close
$1.40
Open
$1.40
Day's High
$1.40
Day's Low
$1.36
Volume
8,928
Avg. Vol
28,826
52-wk High
$3.88
52-wk Low
$1.32

Chart for

About

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to... (more)

Overall

Beta: 0.12
Market Cap(Mil.): $15.08
Shares Outstanding(Mil.): 10.77
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.96 15.25
EPS (TTM): -- -- --
ROI: -- 15.07 33.27
ROE: -- 16.58 16.35

BRIEF-Onconova Therapeutics files for mixed shelf offering of upto $84.5 mln

* Onconova Therapeutics Inc files for mixed shelf offering of upto $84.5 million- SEC filing‍​ Source text: (http://bit.ly/2AiGwl1) Further company coverage:

Nov 20 2017

BRIEF-Onconova Therapeutics announces data on improved formulation of Rigosertib and next-generation CDK4/6 inhibitor

* Onconova Therapeutics announces data on improved formulation of Rigosertib and next-generation CDK4/6 inhibitor at 2017 American Association Of Pharmaceutical Scientists annual meeting Source text for Eikon: Further company coverage:

Nov 16 2017

BRIEF-Onconova Therapeutics prices public offering

* Onconova Therapeutics announces pricing of public offering of common stock

Nov 10 2017

BRIEF-Onconova Therapeutics reports Q3 revenue $100,000

* Onconova Therapeutics, Inc. reports business highlights and third quarter 2017 financial results

Nov 09 2017

BRIEF-Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics

* Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics to develop new phospholipid drug conjugates

Sep 21 2017

BRIEF-Onconova Therapeutics reports qtrly net loss per share of $0.29

* Onconova Therapeutics, Inc. reports recent business highlights and second quarter 2017 financial results

Aug 15 2017

Competitors

Earnings vs. Estimates